In-clinic removal of nasal polyps for chronic sinusitis
Official title: Endoscopic Polypectomy Performed In Clinic for Chronic Rhinosinusitis With Polyps: The EPIC Randomised Controlled Trial
Run by Ottawa Hospital Research Institute · NCT02975310 · Data updated 2026-11-12
This study tests if a new in-clinic procedure for removing nasal polyps can help people with chronic sinusitis just as much as the traditional surgery done in an operating room, while being quicker and cheaper.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Ottawa Hospital Research Institute Academic / other |
| Locations | 4 sites (Vancouver, British Columbia and 3 other locations) |
| Status | Recruiting |
| Started | April 11, 2017 |
| Main results expected | December 2025 |
| Study ends | December 2026 |
| Registry record updated | December 30, 2025 |
| Trial ID | NCT02975310 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with chronic rhinosinusitis with nasal polyps requiring surgical intervention.
✕Probably not a fit
Patients with mild nasal polyps or those who have not responded to medical therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of in-clinic endoscopic polypectomy (EPIC) as a treatment for chronic rhinosinusitis with nasal polyps. The study compares EPIC to traditional endoscopic sinus surgery (ESS) performed in an operating room, focusing on patient outcomes, cost-effectiveness, and quality of life improvements. Participants will undergo the procedure in a clinical setting, which is expected to reduce wait times and costs significantly. The trial aims to provide high-quality evidence on whether EPIC can match the benefits of ESS while being more accessible and affordable.
Why it matters
Potential benefit: If successful, this approach could provide patients with quicker and more cost-effective relief from chronic sinusitis symptoms.
How similar studies have gone: Previous studies have indicated that in-clinic polypectomy may offer similar benefits to traditional surgery, but this trial aims to provide definitive evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 years or older 2. Diagnosis of chronic rhinosinusitis with polyps requiring surgical treatment after having been treated with medical therapy as designated by the Canadian clinical practice guidelines for acute and chronic sinusitis. 15 3. Bilateral nasal polyps present of Grade ≥ 2 on each side as determined by the Lildholdt scale score measured by nasal endoscopy at the screening visit. 4. Must have nasal blockage score greater than or equal to 2 on the sinonasal outcome test SNOT-22 at the screening visit. 5. Must have an American Society of Anesthesiologists physical status PS3 classification or less. 6. Participants with comorbid asthma or chronic obstructive pulmonary disease (COPD) must have stable disease with no exacerbations (no emergency room visits, hospitalisations, or oral or parental steroid use for these lower respiratory conditions) within 3 months before the screening visit. 7. Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Participants must sign an informed consent document indicating that they understand the purpose of and procedures of the study and are willing to participate in the study. Exclusion Criteria: 1. Women who are pregnant or breast feeding as per patient's report 2. Patients with hyperplastic polyps or polyps large enough that they result in external nasal deformity 3. Facial pain/pressure score higher than 2 on the sinonasal outcome test SNOT-22 at the screening visit. 4. History of any surgical procedure that prevents the ability to accurately grade the nasal polyps 5. Participants who will not be able to complete the follow-up appointments/evaluations 6. Have significant oral structural abnormalities, e.g. unrepaired cleft palate 7. Septal deviation requiring correction in order to perform either EPIC or ESS procedures 8. Diagnosis of an immunodeficiency or immunocompromised state 9. Diagnosis of cystic fibrosis 10. Diagnosis of allergic fungal sinusitis 11. Contraindication to the use of oral corticosteroids (e.g. uncontrolled diabetes, congestive heart failure, uncontrolled hypertension, known renal insufficiency, known peptic ulcer disease, known glaucoma, pregnancy) 12. History of either Churg-Strauss syndrome, primary ciliary dyskinesia, or vasculitis (e.g. granulomatosis with polyangiitis(GPA)) 13. Allergy, hypersensitivity, or contraindication to the use of local or topical lidocaine anesthetics, nasal topical 1:1000 adrenaline, nasal decongestants, nasal steroid spray 14. Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator, could confound the results of the study or could interfere with the participant's participation or compliance with the study 15. A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the participant's participation or compliance with the study 16. Inability to read and understand English 17. Any medical condition that in the opinion of the investigator would interfere with the treatment 18. Any participant who is unfit to undergo surgery under general anesthesia 19. Current participation in another clinical trial at the time of the screening visit. 20. Participant is unable to undergo an awake procedure 21. Diagnosis or Aspirin Exacerbated Respiratory Disease (AERD)
Where it's running
-
Vancouver General Hospital
Vancouver, British Columbia, Canada Recruiting -
St. Joseph's Hospital London
London, Ontario, Canada Recruiting -
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada Recruiting -
McGill University Health Center
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Shaun Kilty, MD — Ottawa Hospital Research Institute
- Study coordinator: Andrea Lasso, MSc
- Email: alasso@toh.ca
- Phone: 6137985555
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis with Nasal Polyps
This study tests whether metabolic and immune markers in nasal tissue and blood differ between people with nasal polyps and those without, to help understand CRSwNP and find potential diagnostic clues.
-
GSK5784283 as add-on therapy for chronic rhinosinusitis with nasal polyps
This study tests whether GSK5784283 added to standard care can help adults with chronic rhinosinusitis with nasal polyps feel better and have fewer symptoms.
-
GSK5784283 as add-on maintenance therapy for nasal polyps in chronic rhinosinusitis
This study tests whether adding GSK5784283 (Felcorekibart) to standard care helps people with chronic rhinosinusitis with nasal polyps.
-
Which antibiotic works best for kids with sinus infections?
This study tests whether amoxicillin, amoxicillin-clavulanate, or a placebo help children with acute sinusitis feel better faster.
-
Triamcinolone-loaded nanocapsules after endoscopic nasal surgery
This trial tests whether a triamcinolone acetonide–loaded nanocapsule spray is better than saline irrigation for healing after endoscopic nasal surgery in adults with chronic rhinosinusitis and nasal polyps.
-
Depemokimab monotherapy for chronic rhinosinusitis with nasal polyps in Japanese adults
This study tests depemokimab alone (without intranasal corticosteroids) in adults with chronic rhinosinusitis with nasal polyps in Japan.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.